11/8
02:48 am
rigl
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... [Yahoo! Finance]
High
Report
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... [Yahoo! Finance]
11/7
04:18 pm
rigl
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/7
04:01 pm
rigl
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
07:57 am
rigl
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
Low
Report
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
11/5
09:14 am
rigl
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
Medium
Report
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
11/5
09:05 am
rigl
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
Medium
Report
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
10/31
08:05 am
rigl
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
Low
Report
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
10/25
08:37 am
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Low
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
10/24
04:35 pm
rigl
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
Low
Report
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
10/18
11:01 pm
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Medium
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
10/16
10:00 am
rigl
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
Low
Report
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
10/4
08:05 am
rigl
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
9/25
06:39 am
rigl
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? [Yahoo! Finance]
Medium
Report
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? [Yahoo! Finance]
9/20
01:29 pm
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock.
Low
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock.
9/12
08:05 am
rigl
Rigel to Present at the 2024 Cantor Global Healthcare Conference
Low
Report
Rigel to Present at the 2024 Cantor Global Healthcare Conference
9/6
07:37 am
rigl
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial [Yahoo! Finance]
Low
Report
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial [Yahoo! Finance]
9/5
07:30 am
rigl
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
Medium
Report
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
9/3
11:19 am
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Low
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
9/3
08:00 am
rigl
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
Medium
Report
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
8/29
01:39 pm
rigl
With 45% stake, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) seems to have captured institutional investors' interest [Yahoo! Finance]
Low
Report
With 45% stake, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) seems to have captured institutional investors' interest [Yahoo! Finance]
8/29
08:11 am
rigl
Rigel to Participate in Upcoming September Investor Conferences [Yahoo! Finance]
Medium
Report
Rigel to Participate in Upcoming September Investor Conferences [Yahoo! Finance]
8/29
08:05 am
rigl
Rigel to Participate in Upcoming September Investor Conferences
Medium
Report
Rigel to Participate in Upcoming September Investor Conferences
8/9
06:12 pm
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at HC Wainwright from $15.00 to $57.00. They now have a "buy" rating on the stock.
High
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at HC Wainwright from $15.00 to $57.00. They now have a "buy" rating on the stock.